Cargando…

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model

Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) are promising targets for molecular imaging of prostate cancer (PCa) lesions. Due to the heterogenic overexpression of PSMA and GRPR in PCa, a heterodimeric radiotracer with the ability to bind to both targets co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lundmark, Fanny, Abouzayed, Ayman, Mitran, Bogdan, Rinne, Sara S., Varasteh, Zohreh, Larhed, Mats, Tolmachev, Vladimir, Rosenström, Ulrika, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408065/ https://www.ncbi.nlm.nih.gov/pubmed/32630176 http://dx.doi.org/10.3390/pharmaceutics12070614

Ejemplares similares

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2017)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
por: Varasteh, Zohreh, et al.
Publicado: (2013)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2020)

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26
por: Rinne, Sara S., et al.
Publicado: (2021)

The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a (68)Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin
por: Varasteh, Zohreh, et al.
Publicado: (2014)

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
por: Baun, Christina, et al.
Publicado: (2020)

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
por: Rybalov, Maxim, et al.
Publicado: (2014)

(64)Cu-DOTHA(2)-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
por: Milot, Marie-Christine, et al.
Publicado: (2022)

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
por: Rinne, Sara S., et al.
Publicado: (2019)

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
por: Murce, Erika, et al.
Publicado: (2023)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
por: Murce, Erika, et al.
Publicado: (2023)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
por: Zippel, Claus, et al.
Publicado: (2020)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Preparation and Biological Evaluation of [(99m)Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer
por: Xiao, Di, et al.
Publicado: (2020)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

All that Glitters on PSMA is Not a Lesion: An Unusual Artifact on PSMA PET/CT
por: Dev, Indraja D., et al.
Publicado: (2021)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

In Vivo Biodistribution and Efficacy Evaluation of NeoB, A Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
por: Montemagno, Christopher, et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8uqa354d5m1i4b9kjvmf55vtj2